Members of the TRP superfamily of cation channels have homeostatic and regulatory functions in cells and changes in their expression may contribute to malignant growth. Previously, we have demonstrated that the gene of the Ca 2 þ -selective cation channel CaT-L or TRPV6 is not expressed in benign prostate tissues including benign prostate hyperplasia, but is upregulated in prostate cancer. Here, we report on the differential expression of TRPV6 mRNA in prostate tissue obtained from 140 patients with prostate cancer. Using in situ hybridization, TRPV6 transcripts were undetectable in benign prostate tissue, high-grade prostatic intraepithelial neoplasia (n ¼ 57), incidental adenocarcinoma and all tumors less than 2.3 cubic centimeter (cc). In prostatectomy specimens from 97 clinically organ-confined tumors, TRPV6 expression correlated significantly with the Gleason score (P ¼ 0.032), pathological stage (Po0.001) and extraprostatic extension (P ¼ 0.025). Lymph node metastasis (n ¼ 17) and androgen-insensitive tumors (n ¼ 27) revealed TRPV6 expression in 63 and 67% of cases, respectively. The latter, however, revealed markedly and significantly decreased levels when compared with untreated tumors (P ¼ 0.044). In summary, the data demonstrate that TRPV6 expression is associated with prostate cancer progression. Accordingly, TRPV6 represents a prognostic marker and, as a plasma membrane Ca 2 þ channel, a promising target for new therapeutic strategies to treat advanced prostate cancer. Oncogene (2003 Oncogene ( ) 22, 7858-7861. doi:10.1038 Keywords: prostate cancer; TRPV6; in situ hybridization; prognostic marker; TRP cation channel Prostate cancer is unique among the potentially lethal neoplasias in its high prevalence of clinically insignificant tumors and its much lower prevalence of clinical disease. One of the dilemmas facing urologists today is to identify patients with indolent disease for which treatment is unnecessary and those with fatal disease beyond cure. Despite improvements in early detection through serum prostate-specific antigen (PSA) testing and improved preoperative prediction of stage using normograms and neural networks, the accuracy of predicting the pathological and clinical outcome remains limited (Narayan et al., 1995; Cupp et al., 1995; Steinberg et al., 1997; Wills et al., 1998) . For example, over 50% of clinically organ-confined cancers prior to surgery are locally advanced or metastatic upon pathological analysis and are likely to progress (Partin et al., 1997) . There is an acute need for accurate predictive factors in patients with prostate cancer given the marked variation in treatment recommendations. Accordingly, many efforts are currently pursued as to the molecular staging of prostate cancer to improve the traditional clinicopathological staging.
Previously, we have identified a novel Ca 2 þ -selective channel, TRPV6, originally termed as Ca 2 þ transporterlike protein (CaT-L, Niemeyer et al., 2001; Wissenbach et al., 2001) , Ca 2 þ transporter type 1 (CaT Peng et al., 1999) or epithelial Ca 2 þ channel type 2 (ECaC2, Hoenderop et al., 2001) , which is undetectable in benign prostate tissue, but may be upregulated in prostate cancer . On the basis of that initial finding, we suggested that molecular staging of prostate cancer by monitoring the level of human TRPV6 gene expression may be feasible. We therefore extended our studies on tissue samples obtained from 140 patients with prostate cancer (Table 1) . TRPV6 transcripts were undetectable by in situ hybridization in benign prostate tissue from patients with benign prostatic hyperplasia (BPH) and adjacent to cancer. Seminal vesicles, however, revealed focal TRPV6 mRNA expression in 35 of 39 cases. Incidental adenocarcinoma obtained from 10 specimens by transurethral resectomy (TUR) and all high-grade prostatic intraepithelial neoplasia (HGPIN) present in the radical prostatectomy specimens submitted for study (n ¼ 57) lacked detectable levels of TRPV6 mRNA. Conversely, nontransition zone cancers revealed TRPV6 expression at variable degrees depending on the Gleason score, growth patterns and pathological stages (Table 2) . In general, prostate cancer cells expressing TRPV6 had a close contact with the stroma. This feature was particularly evident in solid and cribriform growth patterns with a band-like expression of TRPV6 mRNA at the site of contact with the host tissue (Figure 1a-g ).
Irrespective of the pathological stages, TRPV6 expression correlated with the histological grade. There was a statistically significant difference between lowgrade (Gleason score o7) and high-grade (Gleason score X7) tumors (P ¼ 0.032). Organ-confined tumors (pT2a,b) revealed TRPV6 transcripts in 20% of the cases (four of 20), but only one tumor showed TRPV6 expression in more than 20% of tumor cells ( Figure 1a ). Locally advanced tumors (pT3a, pT3b) expressed TRPV6 mRNA in 26 of 34 cases (76%), and in 36 of 40 cases (90%; Figure 1b -e). Significant expression, that is, more than 20% of tumor cells expressing TRPV6, was noted in 21% of pT3a and 8% of pT3b tumors (Table 2) . Statistical analyses revealed a highly significant difference in their TRPV6 status between organconfined (pT2a,b) and locally advanced (pT3a,b) tumors (Po0.001).
In prostate cancer with extraprostatic extension, the amount of TRPV6 expression recorded in the extraprostatic component was significantly higher than in organconfined parts of the tumor (P ¼ 0.025). In addition, tumors with seminal vesicle involvement (pT3b) expressed TRPV6 at higher levels than pT3a tumors, but the difference was not statistically significant (P ¼ 0.25). Irrespective of the pathological stages, TRPV6 transcripts were undetectable in primary tumors with less than 2.3 cubic centimeter (cc) cancer volume. Even in positive cases, smaller, secondary cancers with a volume less than 1 cc lacked detectable levels of TRPV6.
The lymph node metastases (Figure 1f , g) submitted for study showed TRPV6 transcripts in 10 of 16 cases (63%). At least three of 16 cases showed extensive TRPV6 expression with more than 50% of tumor cells being positive. When comparing pT3a,b,pN0 and pT3b, pN1 6 (1) 7 (4) 8 (7) 9 (7) 10 (1) (7) (9) 9 pTx, pN1 ND 24
Recurrent carcinomas ND n, number of patients; n*, number of lesions; ND, not determined; HGPIN, high-grade prostatic intraepithelial neoplasia. The Gleason scores refer to the cancerous lesions obtained from 97 radical prostatectomy specimens. Lymph node metastases and recurrent lesions were not graded. Formalin-fixed, paraffin-embedded tissue sections were obtained from 140 prostate cancer patients during a period from 1993 to 2002. This included 97 radical prostatectomy specimens with eight pelvic lymph node metastasis, 10 TUR specimens with incidental prostatic adenocarcinoma, and nine lymph node metastases from staging lymphadenectomy without subsequent prostatectomy and previous hormonal therapy. The material further contained palliative TUR specimens from 24 patients with recurrent prostatic adenocarcinoma after orchiectomy. In addition, 57 foci of high-grade prostatic intraepithelial neoplasia (HGPIN) present in the radical prostatectomy specimens were submitted for study. The extent of HGPIN was arbitrarily defined by one microscopic field at low-power magnification ( Â 100). Finally, 10 TUR specimens with benign prostatic hyperplasia were selected for the study n, number of specimens; n.e., not evaluable; BPT, benign prostate tissue; HGPIN, high-grade prostatic intraepithelial neoplasia, TUR, transurethral resection. The TRPV6 in situ hybridization score was evaluated by a grading system ranging from 0 to 5. The entire cancerous lesion present in each slide was scanned at a power of -square analyses were used to study the relation between the TRPV6 score and the pathological staging or histological grading of primary prostatic adenocarcinoma, recurrent disease and metastases. Statistical analyses were performed with the Statistical Package for Social Sciences software (SPSS ASC GmbH, Erkrath, Germany). Po0.05 was regarded as statistically significant TRPV6 expression in prostate cancer T Fixemer et al pT3a,b,pN1, statistical analyses failed to demonstrate a significant difference in TRPV6 expression between both groups (P ¼ 0.359).
Decreasing levels of TRPV6 were detected in androgen-insensitive tumors after androgen deprivation therapy when compared with primary tumors. In all, 16 of 24 (67%) recurrent tumors revealed TRPV6 transcripts, but only two cases showed TRPV6 expression in more than 20% of tumor cells. Statistical analysis showed a significant decrease of TRPV6 expression in recurrent tumors when compared with untreated primary tumors (P ¼ 0.044). Downregulation of TRPV6 in hormonerefractory tumors under androgen deprivation suggests that transcriptional activities of TRPV6 may be androgen-dependent. This is supported by our analysis of prostate cancer cell lines, showing that the androgensensitive LNCaP expresses detectable levels of TRPV6 transcripts in contrast to the androgen-insensitive PC-3 and DU145 cell lines (Figure 1h ).
TRPV6 has been characterized as a Ca 2 þ -selective cation channel, most probably involved in Ca 2 þ uptake across the plasma membrane and transcellular Ca 2 þ transport. Plasma membrane Ca 2 þ channels are key players regulating numerous physiological cellular functions, and there is growing evidence that calcium signaling is also involved in cell proliferation and cell death (Toyota et al., 1999; Mariot et al., 2002) . The present study demonstrates that TRPV6 expression, as determined by in situ hybridization, correlates with the Gleason score, pathological stage and extraprostatic extension of prostate cancer. In contrast, TRPV6 expression is absent from premalignant prostatic lesions and clinically organ-confined adenocarcinoma of less than 2.3 cc in volume. These features make TRPV6 a promising molecular marker in the preoperative staging for prediction of clinically significant disease and extraprostatic extension. What is needed by future studies is an indication that this new marker adds predictive value to the known markers such as Gleason score or serum prostate-specific antigen in predicting clinical outcome with enough power that clinical decision making will be altered. This warrants further investigations to evaluate its prognostic significance in needle biopsies and in prostatectomy specimens.
In conclusion, the data presented here make TRPV6 one of the first plasma membrane ion channels to be used as marker to classify cancer on a molecular level. RNA isolated from human placenta and the human prostate cancer cell lines PC3, LNCaP, DU145 and the cervix cancer-derived HeLa cell line (2 mg each) as described earlier and probed with a 345-bp (nucleotides 1584 to 1928) human TRPV6 fragment (upper panel). One band of 3.0 kb was visible in the androgen-sensitive LNCaP cells as well as in placenta but not in HeLa cells and the androgen-insensitive prostate cancer cell lines PC3 and DU145. The filter was exposed to X-ray film for 4 days. Signals after hybridization of human GAPDH cDNA as control to the same filters (lower panel). The Northern experiment was repeated at least twice using independent preparations of poly(A þ ) RNA TRPV6 expression in prostate cancer T Fixemer et al
